KPV vs TB-500
Side-by-side comparison of KPV, TB-500 — mechanism, dosing, half-life, side effects, and research status.
| Attribute | KPV KPV (Lys-Pro-Val) — Alpha-MSH Tripeptide Recovery | TB-500 Thymosin Beta-4 Synthetic Analogue Recovery |
|---|---|---|
| Basics | ||
| Molecular type | Alpha-MSH C-terminal Tripeptide | Thymic Peptide Analogue |
| Amino acids | 3 | 43 |
| Molecular weight | 355.4 Da | 4,921 Da |
| Half-life | Short (hours) | Long-acting (days) |
| Route(s) | Subcutaneous, Oral (GI conditions), Topical | Subcutaneous, Intramuscular |
| Mechanism & Research | ||
| Primary mechanism | KPV binds melanocortin receptors (MC1R and MC3R) expressed on immune cells, epithelial cells, and neurons. Receptor activation suppresses NF-κB-mediated pro-inflammatory cytokine production (TNF-α, IL-6, IL-8) and drives… | TB-500's primary mechanism involves binding to G-actin (monomeric actin) through its conserved LKKTETQ sequence. By sequestering actin, it regulates cytoskeletal dynamics in ways that promote cell migration — a critical … |
| Research status | Research Compound | Research Compound |
| Evidence summary | KPV has robust preclinical data for inflammatory bowel conditions (Crohn's disease, ulcerative colitis models) and wound healing. Oral nanoparticle formulations have been developed to improve colonic delivery. | TB-500 research spans cardiac regeneration, wound healing, hair follicle regeneration, and musculoskeletal repair. Most data is preclinical. Phase 1/2 trials with native Thymosin Beta-4 for cardiac indications have been … |
| Protocol & Dosing | ||
| Typical dose | 500 mcg–2 mg/day (SC); variable oral dosing | 5–10 mg per injection |
| Frequency | Once or twice daily | 2x per week (loading), then weekly |
| Duration | 4–8 weeks | 4–8 weeks |
| Timing | Any time; pre-meals for GI applications | No specific timing requirement |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Not Prohibited | Prohibited (WADA S2) |
| Deeper reading | ||
| Related peptides | BPC-157, LL-37, TB-500 | BPC-157, GHK-Cu, Thymosin Alpha-1 |
| Full profile | Read full KPV profile → | Read full TB-500 profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.